Breaking News
February 21, 2019 - Brief Anesthesia in Infancy Does Not Mar Neurodevelopment
February 21, 2019 - Gaming system helps with autism diagnosis
February 21, 2019 - Heart Disease: Six Things Women Should Know
February 21, 2019 - More States Say Doctors Must Offer Overdose Reversal Drug Along With Opioids
February 21, 2019 - Researchers explore case studies focused on industries that kill more people than employed
February 21, 2019 - Intense exercise, fasting and hormones can enhance waste-protein removal, study shows
February 21, 2019 - Scientists can monitor brain activity to predict epileptic seizures few minutes in advance
February 21, 2019 - Study quantifies hepatic and intestinal mRNA expression of Ugt isoforms in rats
February 21, 2019 - ‘Apple-Shaped’ Body? ‘Pear-Shaped’? Your Genes May Tell
February 21, 2019 - Can we repair the brain? The promise of stem cell technologies for treating Parkinson’s disease
February 21, 2019 - Trump Plan To Beat HIV Hits Rough Road In Rural America
February 21, 2019 - PENTAX Medical introduces new electrosurgical and argon plasma coagulation platforms
February 21, 2019 - Trump plan to beat HIV hits rough road in rural America
February 21, 2019 - Eating blueberries every day could help decrease blood pressure
February 21, 2019 - ‘No Second Chances’ report calls for new measures to combat cardiovascular disease in Australia
February 21, 2019 - Mayo clinic researchers discuss local case studies of leprosy
February 21, 2019 - Scientists demonstrate key role of salt in allergic immune reactions
February 21, 2019 - Experts propose revising the criteria for diagnosis of Parkinson’s disease
February 21, 2019 - The med student and the machine
February 21, 2019 - Hey, Hey! Ho, Ho! Is Striking For School Nurses The Way To Go?
February 21, 2019 - Latest research encourages children to move out and learn through physical activity
February 21, 2019 - Proper oral hygiene and regular visits to dentist can promote heart health
February 21, 2019 - New, versatile technique for remote control of transplanted cells in Parkinson’s
February 21, 2019 - Why melanoma tumors in the brain may be worse?
February 21, 2019 - New project aims to improve lung disease care in Appalachia
February 21, 2019 - Drug increases melanin production in some people with albinism
February 21, 2019 - Over 1 in 3 adults miss the mark on protein, finds study
February 21, 2019 - CymaBay Therapeutics Announces Seladelpar Granted Breakthrough Therapy Designation by the FDA for the Treatment of Primary Biliary Cholangitis
February 21, 2019 - A correlation between obesity and income has only developed in the past 30 years
February 21, 2019 - Baby, then work: An effort to help resident-parents in emergency medicine
February 21, 2019 - Heavy cigarette smoking could damage vision, say researchers
February 21, 2019 - Some drug combinations may be more effective than others for schizophrenic patients
February 21, 2019 - Combination of common antibiotics can eliminate multi-drug resistant E. coli
February 21, 2019 - Number of calls to U.S. Poison Control regarding kratom exposure increased
February 21, 2019 - New computational tool searches for factors that cause specific diseases
February 21, 2019 - New method to assess effectiveness of psychotherapies for social anxiety disorder
February 21, 2019 - New technology measures hormones that influence reproductive health efficiently
February 21, 2019 - Bat influenza viruses could potentially attack the cells of humans and livestock
February 21, 2019 - Immunotherapeutic antibody therapy to kill cancer has now progressed to patient testing
February 21, 2019 - Johns Hopkins scientists find new compound that may prevent reperfusion injury
February 21, 2019 - Researchers develop new way to deliver treatment for cartilage regeneration
February 21, 2019 - Study sheds new light on left ventricular dysfunction in ischemic heart disease
February 21, 2019 - New technique could expedite cancer diagnosis, lead to better patient outcomes
February 21, 2019 - New map of infant brain may aid early diagnosis of autism
February 21, 2019 - Human consciousness depends on the brain’s ability to maintain dynamics of neural activity
February 21, 2019 - Harmony Biosciences Announces File Acceptance Of Its New Drug Application For Pitolisant
February 21, 2019 - Medications could fill treatment gap for adolescents with obesity
February 21, 2019 - New antibiotics are desperately needed: Machine learning could help | News Center
February 21, 2019 - Researchers develop new computer game for dementia carers
February 21, 2019 - University of Dundee partners with Takeda to develop new treatments for tau pathology
February 21, 2019 - Influenza vaccine may be less effective in elderly patients, finds study
February 21, 2019 - Researchers explain why T cells lose their protective ability in inflamed tissues
February 21, 2019 - New optimization method rapidly analyzes nanomedicines for cancer treatment
February 21, 2019 - Viruses in the intestinal tracts can lead to islet autoimmunity and Type 1 diabetes
February 21, 2019 - Link between dietary fatty acid intake and hypertension found to be influenced by diabetes status
February 21, 2019 - FDA Approves Esperoct (turoctocog alfa pegol, N8-GP) for Hemophilia A
February 21, 2019 - ‘Boy erased’—why conversion therapies and ex-gay ministries should be outlawed
February 21, 2019 - Titia de Lange to give annual McCormick Lecture on March 8 | News Center
February 21, 2019 - Study reveals how helper T cells support memory cells to function optimally
February 21, 2019 - Autistic children with co-occurring ADHD have greater adaptive behavior impairments
February 21, 2019 - Elevated levels of key cellular process implicated in intestinal inflammation and IBD
February 20, 2019 - Over Half of Hip Replacements Expected to Last 25 Years
February 20, 2019 - Microscopic eye movements affect how we see contrast
February 20, 2019 - Computer vs. patient: Fighting for residents’ attention | News Center
February 20, 2019 - New “Smart Drug” Shows Promise for Metastatic Triple-Negative Breast Cancer
February 20, 2019 - Researchers develop large-scale window material for high-efficiency PM2.5 capture
February 20, 2019 - Widespread confusion among consumers on food date labels lead to unnecessary discards
February 20, 2019 - Researchers unlock plant’s secret of producing specialized metabolites
February 20, 2019 - Newly released national framework identifies obstacles to improving EMS systems
February 20, 2019 - Exercise can shift human body clock depending on time when people work out
February 20, 2019 - Female adolescent blood donors more likely to have iron deficiency and related anemia
February 20, 2019 - Rubicon level linked to inhibition of autophagic process
February 20, 2019 - Researchers find potential therapeutic strategy to treat Alzheimer’s
February 20, 2019 - New forms of older anti-cancer agent appear to enhance immune response to fight melanoma
February 20, 2019 - Health Tip: Eat Less Saturated Fat
February 20, 2019 - Sleeping in contact lenses puts you at risk of dangerous infection
February 20, 2019 - “We should study that!”: How a nurse-scientist found her passion
February 20, 2019 - Cervical microbiome may influence HPV infection more than previously thought
February 20, 2019 - Sausage mislabeling in Canada is down, new study finds
February 20, 2019 - Study shows blood pressure benefits of morning exercise for older overweight/obese adults
A Stable and Specific way to Target Cells in the Nervous System

A Stable and Specific way to Target Cells in the Nervous System

image_pdfDownload PDFimage_print

An interview with Eugenia Kuteeva conducted at SfN 2018, by Alina Shrourou, BSc.

How can Neuroscience markers be used to advance our understanding of the brain?

Neuroscience markers are monoclonal antibodies, developed for identification of the main anatomical and histochemical cell types in the central nervous system. They can therefore be used as markers of the structural and chemical neuroanatomy. These antibodies can also be employed in multiplexing studies, to look, for example, at the expression of your protein of interest in a particular cell type in the nervous system.

Please outline the Neuroscience Marker Panel provided by Atlas Antibodies and which neural lineage and signalling markers they can target.

Our Neuroscience marker panel antibodies are a part of our catalogue of monoclonal antibodies. They target the main cell types in the nervous system, including neurons, astrocytes and oligodendrocytes. We will soon be adding also some microglial markers, which are currently under development. And already now we provide markers for the main neurotransmitter systems, including GABA, glutamate, acetylcholine, dopamine and serotonin systems.

How do Atlas Antibodies develop and validate these markers?

It is important to mention that we have chosen the targets for development of the Neuroscience markers antibodies, based on scientific knowledge on most relevant proteins for identification of different cell types in the brain.

We have an established protocol for development of our monoclonal antibodies, which starts with a careful selection of the most appropriate antigen for immunization. Following immunization, a number of ELISA positive clones are tested in functional applications in order to select the optimal ones for establishing the hybridomas, from which the purified monoclonal antibodies are finally produced. We test the purified monoclonal antibodies thoroughly in all relevant applications before approving and releasing them as products. In addition, all PrecisA Monoclonals are supported with isotype and, when relevant, epitope data.

We put a great effort into the proper validation of our antibodies by following the directions of the International Working Group for Antibody Validation (IWGAV), which recommends the five pillars of validation – genetic, orthogonal, independent antibody, expression of tagged proteins and immunocapture mass spectrometry. We apply these guidelines when validating our antibodies, which we do in the application specific manner.

Furthermore, the majority of PrecisA Monoclonals within the Neuroscience marker panel are tested and approved for use in both human, mouse and rat tissues, which can be beneficial for e.g. translational studies.

What are the other areas of research you provide the antibodies for?

Alongside our Neuroscience marker panel monoclonals, we also have monoclonal antibodies targeting early development of the nervous system, cortical layers markers, as well as organelle, SOX proteins, stem cells and EMT markers to name a few.

On our website, we provide information about the applications and species, which antibodies have been approved for. For the neuroscience marker panel in particular, we have tested and approved them for immunohistochemistry use in human, mouse, and rat tissues.

What can Atlas Antibodies provide to the neuroscience research community by being at Neuroscience 2018?

We put a great effort into developing the most specific and selective antibodies that meet the researchers needs. We take a great care in ensuring that the antibodies are functioning properly for our customers in all recommended applications.

We are here to meet with and talk to scientists in the neuroscience community. We always look forward to events like SfN to be able to discuss our products with our customers in person and to help them to meet their research challenges by providing technical and scientific advice.


Researchers often come to us to discuss which antibodies can be useful for their studies. For example, whether we have antibodies against their specific targets of interest, or which antibodies can be used for identifying specific cell types, groups of cells or particular structures in the nervous system. They may also have questions on experimental protocols. We are present here with our many years of neuroscience expertise to try to meet up and help scientist with their questions.

About Eugenia Kuteeva

Eugenia Kuteeva is a Principle Scientist working with development and validation of novel monoclonal antibodies (PrecisA Monoclonals) at Atlas Antibodies since 2012. Dr. Kuteeva holds a PhD degree in Neuroscience from the Department of Neuroscience at Karolinska Institute. She has a broad experience in life sciences from both academia and industry. Dr. Kuteeva has received several prestigious grants and has published more than 20 peer reviewed scientific papers, reviews and book chapters.

About author

Related Articles